Archer Investment Corp Invests $283,000 in United Therapeutics Co. (NASDAQ:UTHR)

Archer Investment Corp bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 790 shares of the biotechnology company’s stock, valued at approximately $283,000.

Several other hedge funds have also recently bought and sold shares of the business. ClariVest Asset Management LLC grew its position in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. V Square Quantitative Management LLC bought a new stake in shares of United Therapeutics in the second quarter valued at about $30,000. Innealta Capital LLC bought a new stake in shares of United Therapeutics in the second quarter valued at about $33,000. USA Financial Formulas bought a new stake in shares of United Therapeutics in the third quarter valued at about $33,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics in the third quarter valued at about $82,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Christopher Causey sold 510 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the transaction, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. The trade was a 12.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $344.18, for a total transaction of $1,239,048.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at $44,743.40. This represents a 96.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 113,396 shares of company stock valued at $42,175,418 in the last three months. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $15.60 during midday trading on Friday, reaching $370.67. 63,387 shares of the stock were exchanged, compared to its average volume of 460,716. The business has a 50-day simple moving average of $362.57 and a two-hundred day simple moving average of $326.65. The company has a market capitalization of $16.55 billion, a price-to-earnings ratio of 16.96, a P/E/G ratio of 1.17 and a beta of 0.56. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.38 EPS. Equities research analysts expect that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on UTHR. TD Cowen raised their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Jefferies Financial Group raised their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. The Goldman Sachs Group raised their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. Finally, Bank of America cut their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.